We showed that the INO subtype is a prognostic factor for GBM female patients (HR, 3.2E+ 00; p = 0.014) in a multivariate Cox regression analysis when TP53 mutations, IDH1/2 status, MGMT promoter methylation, Chr7 Gain/Chr10 loss, and INO subtype were jointly analyzed. This evidence concerns the gene MGMT and glioblastoma.